Molidustat

• Description:

  Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC50 values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia[1][2].

• Product Name Alternative:

  BAY 85-3934

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H360, H372

• Target:

  HIF/HIF Prolyl-Hydroxylase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Molidustat.html

• Purity:

  99.70

• Solubility:

  DMSO : 5 mg/mL (ultrasonic)

• Smiles:

  O=C1C(N2N=NC=C2)=CNN1C3=NC=NC(N4CCOCC4)=C3

• Molecular Formula:

  C13H14N8O2

• Molecular Weight:

  314.30

• Precautions:

  H302, H360, H372

• References & Citations:

  [1]Flamme I, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9 (11) :e111838.|[2]Yamamoto H, et al. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Am J Nephrol. 2021;52 (10-11) :884-893.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• CAS Number:

  1154028-82-6